Glenn Gormley was appointed Director of Aktis Oncology, Inc. As of November 6, 2026, Aktis Oncology, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 16, 2026, naming 1 appointment (Form 8-K, April 16, 2026).
Who owns Aktis Oncology, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Aktis Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Aktis Oncology, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Aktis Oncology, Inc. files it.
Also on the record for Aktis Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 14, 2026 | Stake report, Schedule 13G, by Blue Owl Capital Holdings LP | 5.92% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13D, by EcoR1 Capital, LLC | 9.1% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13D, by MPM BIOVENTURES 2018, L.P. | 19.3% of the class | 5%+ stakes | Source |
| January 15, 2026 | Stake report, Schedule 13D, by Eli Lilly and Company | 11.9% of the class | 5%+ stakes | Source |
| January 14, 2026 | Stake report, Schedule 13D, by VV Manager II LLC | 10.9% of the class | 5%+ stakes | Source |
| January 9, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| January 7, 2026 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| January 5, 2026 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| December 19, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Aktis Oncology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aktis Oncology, Inc. and the records around it.
Aktis Oncology, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- Eli Lilly and Company also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Scribe Therapeutics, Inc. (Jul 2026), Ionetix Corp / DE / (Jul 2026)
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), ImageneBio, Inc. (May 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
Watch Aktis Oncology, Inc.
Get an email when Aktis Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aktis Oncology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aktis Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aktis Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-16 | In | Director | 8-K, 2026-04-16 |
Who leads Aktis Oncology, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Glenn Gormley, appointed (filed 2026-04-16).
New leaders reset buying decisions — get the Full Report on Aktis Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Aktis Oncology, Inc., with the record behind each one.
Find candidates like Director at Aktis Oncology, Inc.Every change, in the filing's words
Appointed: Glenn Gormley, Director
On April 15, 2026, the board of directors (the "Board") of Aktis Oncology, Inc. (the "Company") appointed Glenn Gormley, MD, PhD as a Class I director of the Company, effective immediately.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
- Dr. Gormley shall hold office for a term expiring at the 2027 Annual Meeting of the Company's stockholders, which is the next stockholder meeting at which Class I directors will be elected.
- Concurrent with his appointment to the Board, Dr. Gormley was appointed to the newly created Science and Technology Committee of the Board (the "Science and Technology Committee") to serve as Co-Chairperson along with Ken Herrmann, MD, PhD, a current member of the Board.
- Glenn Gormley, MD, PhD, age 72, previously served as Global Head of Research and Development and Senior Executive Officer for Daiichi Sankyo, Ltd., a global pharmaceuticals company, as well as the President and Executive Chairman of Daiichi Sankyo, Inc., its United States subsidiary, from 2009 until 2019.
- From 2019 to 2022 he served as Executive Chairman of Daiichi Sankyo, Inc. Dr. Gormley has also served on the board of directors of Healios k.k.
- (TSE: 4593), a Japanese clinical-stage biotechnology company, since May 2022.
Tools for this story
Each opens in a new tab, filled in for Aktis Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.